Table 1 Patient characteristics at baseline
Variable | Cohort before matching (n = 134) | Cohort after matching (n = 90) | ||||
|---|---|---|---|---|---|---|
ETN starters (n = 60) | ADA starters (n = 74) | P | ETN starters (n = 45) | ADA starters (n = 45) | P | |
Demographics | ||||||
Age in years, median (IQR) | 8.6 (5.1 – 13.5) | 10.7 (6.1 – 14.9) | 0.18 | 8.0 (5.3 – 13.9) | 9.8 (5.9 – 14.7) | 0.57 |
Country, n (%) | 0.05 | 1.00 | ||||
Czech Republic | 13 (21.7%) | 9 (12.2%) | 9 (20.0%) | 8 (17.8%) | ||
France | 11 (18.3%) | 7 (9.5%) | 6 (13.3%) | 5 (11.1%) | ||
Greece | 5 (8.3%) | 20 (27.0%) | 5 (11.1%) | 5 (11.1%) | ||
Italy | 19 (31.7%) | 20 (27.0%) | 16 (35.6%) | 18 (40.0%) | ||
Latvia | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | ||
Lithuania | 2 (3.3%) | 1 (1.4%) | 2 (4.4%) | 1 (2.2%) | ||
Netherlands | 9 (15.0%) | 8 (10.8%) | 6 (13.3%) | 7 (15.6%) | ||
Norway | 1 (1.7%) | 2 (2.7%) | 1 (2.2%) | 1 (2.2%) | ||
Poland | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | ||
Singapore | 0 (0.0%) | 2 (2.7%) | 0 (0.0%) | 0 (0.0%) | ||
Slovakia | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | ||
Spain | 0 (0.0%) | 2 (2.7%) | 0 (0.0%) | 0 (0.0%) | ||
Clinical characteristics | ||||||
Disease duration in years, median (IQR) | 2.4 (1.2 – 5.4) | 1.8 (0.8 – 4.1) | 0.19 | 2.9 (1.3 – 5.1) | 1.5 (0.8 – 4.4) | 0.31 |
ILAR category, n (%) | 0.21 | 1.00 | ||||
ERA | 7 (11.7%) | 17 (23.0%) | 6 (13.3%) | 7 (15.6%) | ||
Persistent oligoarthritis | 14 (23.3%) | 21 (28.4%) | 13 (28.9%) | 13 (28.9%) | ||
Extended oligoarthritis | 8 (13.3%) | 7 (9.5%) | 5 (11.1%) | 5 (11.1%) | ||
Polyarthritis RF- | 21 (35.0%) | 24 (32.4%) | 18 (40.0%) | 16 (35.6%) | ||
Polyarthritis RF + | 4 (6.7%) | 1 (1.4%) | 0 (0.0%) | 1 (2.2%) | ||
Psoriatic arthritis | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | ||
Undifferentiated arthritis | 6 (10.0%) | 3 (4.1%) | 3 (6.7%) | 3 (6.7%) | ||
Active joint count, median (IQR) | 3.0 (2.0 – 7.0) | 3.0 (1.0 – 4.8) | 0.15 | 3.0 (1.0 – 6.0) | 3.0 (1.0 – 5.0) | 0.69 |
Co-medication, n (%) | ||||||
NSAIDs | 20 (33.3%) | 16 (21.6%) | 0.19 | 16 (34.8%) | 10 (22.2%) | 0.24 |
Steroids | 9 (15.0%) | 12 (16.2%) | 1.00 | 6 (13.0%) | 5 (11.1%) | 1.00 |
Synthetic DMARDs | 47 (78.3%) | 61 (82.4%) | 0.71 | 35 (80.4%) | 38 (84.4%) | 0.59 |
Patient/parent-reported outcomes | ||||||
Adverse events on MTX | 20 (33.3%) | 27 (36.5%) | 0.84 | 16 (35.6%) | 16 (35.6%) | 1.00 |
VAS pain, median (IQR) | 4.0 (1.8 – 6.0) | 3.3 (0.63 – 6.4) | 0.25 | 4.0 (2.0 – 6.0) | 4.5 (1.0 – 6.5) | 0.90 |
VAS well-being, median (IQR) | 3.0 (1.5 – 5.1) | 4.0 (1.1 – 6.0) | 0.74 | 4.0 (2.0 – 6.0) | 4.0 (1.5 – 6.0) | 0.78 |